Recce Pharmaceuticals Ltd (ASX: RCE) Share Price and News

Mr Graham has experience in marketing, business development and commercialisation of early-stage technologies. Mr Graham's tenure, corporate knowledge and alignment to Recce Pharmaceuticals Ltd as one of its shareholders participating in almost every capital raise to date, demonstrates his capability and conviction to execute and deliver the Company's strategy. He is member of the Risk Management Committee.

Mr McKeough has experience serving as a director in sectors, including for companies involved in professional services, corporate services, regulatory technology, sports technology, charities, health, biotech, child care and education. He is Chairman of the Risk Management Committee.

Dr Dunton has held leadership positions at biotechnology and pharmaceutical companies including serving as president and chief executive officer at Panacos Pharmaceuticals, Inc., Metaphore Pharmaceuticals, Inc., and chief operating officer at Emisphere Technologies, Inc. Dr Dunton served in several positions at Johnson and Johnson including president and managing director at the Janssen Research Foundation where he was responsible for leading over 2,000 professionals worldwide and prior to this as vice president of global clinical research and development at the R.W. Johnson Pharmaceutical Research Institute. During his career, Dr Dunton has been responsible for the approval of approximately 20 New Drug Applications; an amalgamation of prescription and OTC products. He is Member of the Risk Management Committee. Directorships held in other listed entities during the last three years include Palatin Technologies, Inc. (NYSE: PTN); Oragenics, Inc. (NYSE: OGEN); CorMedix, Inc. (NYSE: GRMD).

Ms Dilizia previously had a executive career in public relations and marketing for a retail chain. Ms Dilizia was a market research consultant, which included marketing development of health-care and pharmaceutical products.

Dr Prendergast is currently Non-Executive Chairman and Co-Founder of Palatin Technologies developing targeted therapeutics for the treatment of diseases with unmet medical need and Lead Director of Nighthawk Biosciences, Inc., a publicly traded, clinical stage immunomodulatory company. He was previously a member of the board of the life science companies, Avigen, AVAX Technologies and MediciNova Inc and also as a member of the Advisory Board for the Institute for the Biotechnology of Infectious Diseases (IBID) at the University of Technology Sydney, now called the ithree Institute. Prior to that he was a Managing Director of The Castle Group Ltd., a New York medical venture capital firm. Dr Prendergast held Post-Doctoral Fellowships in the Department of Biochemistry and Molecular Biology, Harvard University and at the Center for Research on Blood Diseases in Paris with Professor Jean Dausset (Nobel Prize, 1980). During his career, Dr Prendergast has been responsible for the approval of three (3) New Drug Applications. He is Member of the Risk Management Committee. Directorships held in other listed entities during the last three years include Heat Biologics, Inc. (NASDAQ: HTBX).

Dr Ward held a technical speciality and special project leadership role with Pfizer Pharmaceuticals, involving providing data for the regulatory submissions to the FDA and TGA. After Pfizer, he was the Laboratory Manager for Solbec, involving, again as presently, drug specifications and pharmaceutical trials for the ASX-Listed company. Most recently, he was Quality Manager at Phebra and responsible for product quality, product introduction and release of all drugs of the company with the TGA.

-

-

-

-